deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 7-arm NCT03893955

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors

Sponsor: AbbVie

Conditions Advanced Solid Tumors Cancer Metastatic Solid Tumors Non-small-cell-lung-cancer (NSCLC) Triple-Negative Breast Cancer (TNBC)
Interventions ABBV-181 ABBV-368 ABBV-927 Carboplatin Nab-paclitaxel
Updated 18 times since 2019 Last updated: Aug 7, 2025 Started: May 21, 2019 Primary completion: Mar 31, 2026 Completion: Mar 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Solid Tumors and Cancer and is currently ongoing. AbbVie leads this study, which shows 18 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Oct 2019 · 3 months · monthly snapshot~Oct 2019 – ~Apr 2020 · 6 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Jun 2024 · 15 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Mar 2023 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 13 earlier versions

  1. Feb 2023 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE1

  3. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

  4. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1

  5. Feb 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  6. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE1

  7. Sep 2021 — Jan 2022 [monthly]

    Recruiting PHASE1

  8. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  9. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  10. Oct 2019 — Apr 2020 [monthly]

    Recruiting PHASE1

  11. Jul 2019 — Oct 2019 [monthly]

    Recruiting PHASE1

  12. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  13. Apr 2019 — Jun 2019 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Clermont-Ferrand, France , Dallas, United States , Durham, United States , Fairfax, United States , Fort Wayne, United States , Huntersville, United States , Lyon, France , Madrid, Spain , Málaga, Spain and 14 more locations